Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
-
Nihon Shokakibyo Gakkai Zasshi · Apr 2016
Case Reports[A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
Regorafenib is recommended as a third-line treatment for unresectable gastrointestinal stromal tumors (GIST). It is usually administered in a repeating cycle of three-weeks on and one-week off. ⋯ As a result, the adverse events were improved and the antitumor effect against the GIST was retained. The continuous administration of reduced-dose regorafenib could be considered a viable dosage adjustment in specific situations.